GET DAILY SIGNALSImmuCell (ICCC): Can the Stock Reach a +27% Gain to $13?
Key Takeaways
- The $13 central target is not an analyst consensus; it reflects a publicly discussed valuation of roughly $12.80 per share (about $116 million), based on a 20x multiple of ImmuCell's fiscal 2025 adjusted EBITDA of about $5.8 million.
- With ICCC trading near $10.26, reaching $13 would require a gain of roughly 27%, a substantial move.
- ImmuCell has essentially no active sell-side price targets; coverage consists of a ratings service and a single long-standing analyst name with no current target, so a fallback, publicly discussed objective is used here.
- The strongest supports are accelerating sales (preliminary Q3 2026 product sales up 46% year over year), rising U.S. market share, and an $8 million capacity expansion program.
- The biggest risks are thin and volatile earnings, gross-margin pressure, a sharp decline in international sales, and a premium small-cap valuation.
- For more context, explore the ticker's Major News, Today's Price Move, Forecast, and Earnings pages.
How the $13 Target Came About
ImmuCell Corporation (NASDAQ: ICCC), a Portland, Maine-based animal health biologics company focused on dairy and beef cattle, is thinly followed by Wall Street. Market data providers show a consensus rating rather than a meaningful price target, and the only named coverage is a long-standing analyst with no current target figure. Because no usable analyst price target exists, this article uses the fallback approach: a price objective that is actually discussed in public market commentary.
That objective comes from independent special-situation research, which notes that after excluding one-time charges, ImmuCell's fiscal 2025 adjusted EBITDA was roughly $5.8 million. Applying a 20x multiple produces a value near $116 million, or approximately $12.80 per share, often rounded to about $13. This is a valuation-based discussion point, not a guarantee or an official consensus, and it sits above the stock's 52-week high of $12.10. When I reviewed comparable names in the space, I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Current Market Position and Path Toward the Target
ImmuCell's stock closed near $10.26 in late October 2026, giving the company a market capitalization of roughly $93 million. The 52-week range runs from $4.52 to $12.10, and the shares have risen more than 60% over the past year. Reaching $13 from $10.26 implies a gain of about 27%, which is a substantial move for a micro-cap with average daily volume in the low thousands of shares.
The path toward that level would likely depend on continued execution in the core First Defense calf-scours franchise. ImmuCell reported record first-quarter 2026 product sales of $10.4 million and preliminary third-quarter sales of $8.0 million, up 46% year over year, with nine-month sales up about 28%. Management's stated plan to expand manufacturing capacity to more than triple current output by 2027 is central to the growth narrative, though near-term gross margin has been pressured by lower manufacturing yields and product-mix shifts.
What Could Support a Move Toward the Target
- Sales momentum: Preliminary Q3 2026 product sales rose 46% year over year, and Tri-Shield First Defense grew about 51%.
- Market-share gains: ImmuCell has expanded its share of U.S. calf-scours category spending from about 29% in 2021 toward 35%, supported by a larger sales team and improved product availability.
- Capacity expansion: An $8 million program aims to roughly triple output and shorten processing times, easing the supply constraints that historically limited growth.
- Strategic refocus: Management has narrowed its focus to the calf-scours market and discontinued the Re-Tain mastitis program, improving operational clarity.
- Balance sheet: The company holds cash of roughly $8.9 million and has generated positive operating cash flow in recent quarters.
What Could Prevent the Target From Being Reached
- Thin profitability: Trailing twelve-month EPS is only about $0.07, leaving a very high P/E ratio that leaves little room for disappointment.
- Margin volatility: Q2 2026 gross margin fell to about 34% from roughly 44% a year earlier on manufacturing yields and product mix, and results have been aided by a one-time $2 million legal settlement.
- International weakness: International sales fell sharply, including a roughly 39% drop in Q2 2026, partly reflecting distributor destocking.
- Concentration and liquidity: The business relies on a narrow product portfolio and a small number of distributors, while micro-cap liquidity can amplify price swings.
- Valuation premium: Even with improving fundamentals, the shares trade at a substantial premium to peers on earnings-based measures, raising the bar for further multiple expansion.
Technical Levels and Market Structure
The most durable reference points are the 52-week high of $12.10 and the 52-week low of $4.52. Because the $13 target sits just above the 52-week high, that $12.10 level functions as a notable resistance zone and potential breakout area. The stock crossed back above its 200-day moving average earlier in 2026 after a strong advance, reflecting a repaired long-term trend, but the $10.00 round-number level and the prior trading range near $8.50 to $9.50 are nearby support areas to monitor on any pullback.
Time Horizon and What Investors Should Monitor
The $13 figure is a valuation discussion point rather than a dated analyst target, so it carries no formal time horizon. In practice, valuation-based objectives of this kind are usually assessed over roughly a twelve-month window, but no specific period is implied. Investors should watch the next quarterly report, scheduled for mid-November 2026, along with guidance on gross margin, manufacturing yields, the pace of capacity-expansion spending, and any recovery in international sales. Because analyst coverage is minimal, company-issued updates on sales and margin trajectory will likely matter more than consensus revisions.
Final Assessment
Can ICCC reach $13? The target rests on a publicly discussed valuation of roughly $12.80 per share, derived from a 20x multiple of adjusted EBITDA, rather than on sell-side analyst coverage, which is effectively absent. Reaching it would require about a 27% advance from the current price near $10.26. The clearest supports are accelerating product sales, rising U.S. market share, and a capacity-expansion program that could lift output and, eventually, margins. The principal obstacles are thin and volatile earnings, recent gross-margin compression, weak international sales, and a premium valuation that leaves little cushion for setbacks. Investors should watch the upcoming earnings report, margin trends, and capacity execution, and should treat the $13 figure as a discussion point rather than a forecast.
AI Daily Buy/Sell Signals
For traders tracking names like ICCC, I find Tickeron's AI Daily Buy/Sell Signals helpful as a complementary, data-driven view. The system uses artificial intelligence to continuously monitor thousands of stocks and ETFs and generate Buy, Sell, or Hold signals from changing market conditions, technical behavior, and AI-driven analysis. This can help traders discover opportunities, monitor existing positions, and spot shifting trends more efficiently than manual review alone. Traders looking for an automated edge in a fast-moving micro-cap environment can explore these AI-generated signals as part of a broader research process.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
Momentum Indicator for ICCC turns positive, indicating new upward trend
ICCC saw its Momentum Indicator move above the 0 level on October 13, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 123 similar instances where the indicator turned positive. In 100 of the 123 cases, the stock moved higher in the following days. The odds of a move higher are at 81%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Moving Average Convergence Divergence (MACD) for ICCC just turned positive on October 13, 2026. Looking at past instances where ICCC's MACD turned positive, the stock continued to rise in 36 of 47 cases over the following month. The odds of a continued upward trend are 77%.
ICCC moved above its 50-day moving average on October 13, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for ICCC crossed bullishly above the 50-day moving average on October 16, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 15 of 20 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 75%.
Following a +1.14% 3-day Advance, the price is estimated to grow further. Considering data from situations where ICCC advanced for three days, in 185 of 242 cases, the price rose further within the following month. The odds of a continued upward trend are 76%.
The Aroon Indicator entered an Uptrend today. In 104 of 140 cases where ICCC Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 74%.
Bearish Trend Analysis
The 10-day RSI Indicator for ICCC moved out of overbought territory on October 14, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 23 similar instances where the indicator moved out of overbought territory. In 20 of the 23 cases, the stock moved lower in the following days. This puts the odds of a move lower at 87%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 52 of 64 cases where ICCC's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 81%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ICCC declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 72%.
ICCC broke above its upper Bollinger Band on October 13, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 2 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 41 (best 1 - 100 worst), indicating steady price growth. ICCC’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 88 (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 91 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ICCC’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.
The Tickeron Valuation Rating of 100 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.970) is normal, around the industry mean (3.037). ICCC's P/E Ratio (128.250) is considerably higher than the industry average of (-1.223). Projected Growth (PEG Ratio) (8.610) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (135.883) among similar stocks. P/S Ratio (2.847) is also within normal values, averaging (439.237).
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of products for cattle health
Industry Biotechnology
Advertisement